HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Emerging drugs for the treatment of cervical cancer.

AbstractINTRODUCTION:
Worldwide, most cervical cancer (CC) patients require the use of drug therapy either adjuvant, concurrent with radiation or palliative.
AREAS COVERED:
This review briefly discusses the current achievements in treating CC with an emphasis in emerging agents.
EXPERT OPINION:
Concurrent cisplatin with radiation and lately, gemcitabine-cisplatin chemoradiation has resulted in small but significant improvements in the treatment of locally advanced and high-risk early-stage patients. So far, only antiangiogenic therapy with bevacizumab added to cisplatin chemoradiation has demonstrated safety and encouraging results in a Phase II study. In advanced disease, cisplatin doublets yield median survival rates not exceeding 14 months. The first Phase III study of bevacizumab, added to standard chemotherapy cisplatin- or non-cisplatin-containing doublet, has shown significant increase in both overall survival and progression-free survival. Further studies are needed before bevacizumab plus chemotherapy can be considered the standard of care for advanced disease. The characterization of the mutational landscape of CC and developments of novel targeted therapies may result in more effective and individualized treatments for CC. The potential efficacy of knocking down the key alterations in CC, E6 and E7 human papilloma virus oncoproteins must not be overlooked.
AuthorsAlberto Serrano-Olvera, Lucely Cetina, Jaime Coronel, Alfonso Dueñas-González
JournalExpert opinion on emerging drugs (Expert Opin Emerg Drugs) Vol. 20 Issue 2 Pg. 165-82 (Jun 2015) ISSN: 1744-7623 [Electronic] England
PMID25578210 (Publication Type: Journal Article, Review)
Chemical References
  • Antineoplastic Agents
Topics
  • Animals
  • Antineoplastic Agents (administration & dosage, therapeutic use)
  • Chemotherapy, Adjuvant (methods)
  • Disease-Free Survival
  • Drug Design
  • Female
  • Humans
  • Molecular Targeted Therapy
  • Precision Medicine
  • Survival
  • Uterine Cervical Neoplasms (drug therapy, pathology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: